论文部分内容阅读
目的 探讨在非小细胞肺癌治疗中,采用恩度联合化疗治疗方法后,取得的临床效果,以及该治疗方案的安全性.方法 选取我院2015G8-2016G860例非小细胞肺炎患者作为研究对象.将患者分为观察组与对照组.每组各30例.对照组采取化学药物治疗.观察组在化学药物治疗的基础上,联合使用恩度治疗.对比两组患者的总有效率和不良反应率.结果 观察组的总有效率为833%,对照组的总有效率为60%.与对照组相比,观察组的总有效率更高.差异显著,P<005,具有统计学意义.其次,观察组的不良反应率为30%,对照组的不良反应率为333%.两组不良反应率差异不明显,P>005.结论 在非小细胞肺癌治疗中,应用恩度联合化疗治疗后,取得了良好的治疗效果.该治疗方法不会产生明显的不良反应,具有很高的安全性、可靠性.因此,值得在临床上大力推广.
Objective To investigate the clinical effect and the safety of this treatment regimen in the treatment of non-small cell lung cancer (NSCLC) combined with entecavir chemotherapy.Methods Eight hundred and sixty-six patients with non-small cell pneumonia in 2015G8-2016G were enrolled in this study. The patients were divided into observation group and control group, with 30 cases in each group.The control group was treated with chemical drugs.The observation group was treated with Endostar on the basis of chemical drugs treatment.Compared with the two groups, the total effective rate and adverse reaction rate Results The total effective rate of the observation group was 833% and the total effective rate of the control group was 60% .The total effective rate of the observation group was higher than that of the control group, the difference was significant, P <005, with statistical significance , The adverse reaction rate was 30% in the observation group and 333% in the control group.The difference in adverse reaction rate was not significant between the two groups (P> 005) .Conclusion In the treatment of non-small cell lung cancer, , And achieved a good therapeutic effect.This treatment does not produce significant adverse reactions, with high safety and reliability.Therefore, it is worth to clinically promote.